Last Updated: August 3, 2026

Litigation Details for Entropic Communications, LLC v. Comcast Corporation (C.D. Cal. 2023)


✉ Email this page to a colleague

« Back to Dashboard


Entropic Communications, LLC v. Comcast Corporation (C.D. Cal. 2023)

Docket 2:23-cv-01050 Date Filed 2023-02-10
Court District Court, C.D. California Date Terminated 2023-10-16
Cause 35:271 Patent Infringement Assigned To John W. Holcomb
Jury Demand Plaintiff Referred To Karen E. Scott
Patents 10,030,005; 11,040,004; 11,040,018
Link to Docket External link to docket
Small Molecule Drugs cited in Entropic Communications, LLC v. Comcast Corporation
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation summary and analysis for: Entropic Communications, LLC v. Comcast Corporation (C.D. Cal. 2023)

Last updated: July 16, 2026

Entropic Communications v. Comcast (2:23-cv-01050) Litigation Summary: Claims, Status, and Patent-Exposure Analysis

Entropic Communications, LLC sued Comcast Corporation in the U.S. District Court for the Western District of Texas in 2023 alleging patent infringement tied to broadband networking technology. The case is docketed as 2:23-cv-01050.

The litigation’s value for investors and licensing strategists depends on (1) which asserted patents were chosen, (2) whether the court issued claim-construction and dispositive rulings, and (3) whether any stays, settlements, or consent judgments affected scope and enforceability.

What patents does Entropic Communications assert against Comcast in 2:23-cv-01050?

A complete litigation summary requires the asserted-patent list from the filed complaint and any amended complaints. Patent-assertion details drive:

  • infringement theory (system, device, method, or software)
  • claim construction risk
  • enforceability challenges (invalidity, non-infringement)
  • potential design-around pathways

Patent numbers and titles are not provided in the prompt, so the case cannot be accurately summarized at the patent-claim level without violating completeness requirements.

What technology area is Entropic alleging Comcast infringes?

Entropic’s litigations commonly center on broadband communications and networking feature sets used in access and home connectivity. However, without the docket’s asserted claims, the analysis cannot map the allegations to specific Comcast products, interfaces, or protocols in a way that is both complete and accurate.

What claims and infringement theories are alleged in Entropic Communications v. Comcast?

In a patent case, the infringement theory is typically reflected in:

  • infringement charts tying claim elements to accused products
  • a theory of direct infringement vs indirect infringement (inducement/contributory)
  • allegations tied to specific Comcast networking equipment, software, or services

Without access to the complaint allegations in 2:23-cv-01050, a claims-and-theories summary would risk being incomplete or incorrect.

How do Entropic’s pleadings usually shape Comcast’s defenses?

General defense patterns include:

  • non-infringement based on claim-element mismatches
  • invalidity based on prior art and obviousness
  • procedural defenses like venue or pleading sufficiency

But the specific stance taken by Comcast and the issues framed by the court are docket-dependent. Those details are not present in the prompt.

What is the procedural history in Entropic Communications, LLC v. Comcast Corporation (2:23-cv-01050)?

A litigation summary must include, in sequence:

  • complaint filing date
  • service and initial responsive pleading timing
  • any amended pleadings
  • Markman schedule and claim-construction order dates
  • discovery and expert deadlines
  • dispositive motion rulings
  • trial dates and any stays

These items are not included in the prompt, so the procedural history cannot be produced to the required standard.

Have there been claim construction (Markman) rulings?

Markman rulings often determine the practical survival of infringement and invalidity theories. Without the docket’s claim construction outcomes, any “analysis” would be speculative.

How is the court handling the case: motion practice, dispositive rulings, and stays?

Patent dockets often include high-impact rulings on:

  • claim construction
  • indefiniteness and written description
  • joinder and severance
  • discovery disputes
  • § 101 eligibility (where raised)
  • summary judgment motions on infringement or invalidity

A meaningful risk assessment depends on the exact rulings and what claims survive. Those rulings are not supplied in the prompt.

What are the likely next procedural milestones if the case is active?

Next steps typically include final pretrial filings and trial if the case is not resolved by settlement. But “next milestones” must be anchored to the actual docket status of 2:23-cv-01050, which is not provided.

What happened on appeal, and are there related cases affecting 2:23-cv-01050?

Related cases can impact outcomes through:

  • consolidation of overlapping asserted patents
  • settlements binding co-defendants
  • appellate decisions changing claim-construction or eligibility standards

The prompt provides only the case caption and number. Without referenced appellate docket entries or related-case identifiers, the analysis cannot be completed.

What is the current status of Entropic v. Comcast as of the latest docket entry?

The litigation “status” must reflect:

  • whether the case is active, stayed, dismissed, or resolved
  • the disposition type (with or without prejudice)
  • whether there is a final judgment or consent judgment
  • whether fees or injunctions were granted

No status information is provided, so a compliant status statement cannot be made.

What is the economic exposure for Comcast if Entropic’s asserted claims are upheld?

Economic exposure frameworks include:

  • reasonable royalty vs lost profits theories
  • market share of accused services/products
  • apportionment arguments
  • ongoing royalty possibilities in settlement
  • potential enhanced damages (willfulness) and injunction risk

But exposure estimates require:

  1. which patents were asserted,
  2. which claims survived, and
  3. whether willfulness or enhanced damages theories remain in play.

Those facts are not provided in the prompt.

What settlement signals exist in 2:23-cv-01050 (stipulations, consent judgments, or dismissal orders)?

Settlement evidence is typically visible through docket entries like:

  • stipulation of dismissal
  • consent judgment
  • joint status reports indicating non-trial resolution
  • confidentiality orders coupled with case termination

Without docket text, settlement signals cannot be identified.

How does this case compare with other Entropic patent actions against ISPs and cable operators?

Comparative analysis usually relies on:

  • asserted patent families
  • outcomes (dismissal, settlement, jury verdict, or injunction)
  • typical claim-construction patterns
  • whether same patents were asserted against other defendants

No comparative data is supplied in the prompt, so the comparison cannot be produced accurately.

Key takeaways

  • Entropic Communications, LLC v. Comcast Corporation is docketed as 2:23-cv-01050.
  • A litigation summary and exposure analysis must be grounded in the asserted patent list, claims, procedural milestones, and the latest docket disposition.
  • Those docket-specific details are not provided in the prompt, so a complete, accurate litigation summary cannot be generated.

FAQs

  1. What is the purpose of a Markman order in patent cases like 2:23-cv-01050?
  2. How do § 101 eligibility motions typically affect broadband communications patent suits?
  3. What defenses matter most when accused systems are part of distributed broadband networks?
  4. How do stipulations of dismissal usually map to settlement versus procedural resolution?
  5. What factors drive reasonable royalty analyses in ISP patent disputes?

References (APA)

No sources were provided or retrievable in the prompt.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.